Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. (2014)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(14)70243-8

PubMed Identifier: 24924991

Publication URI: http://europepmc.org/abstract/MED/24924991

Type: Journal Article/Review

Volume: 15

Parent Publication: The Lancet. Oncology

Issue: 8

ISSN: 1470-2045